Key facts

Active substance
Botulinum toxin type A
Therapeutic area
Cardiovascular diseases
Decision number
PIP number
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Prevention of post-operative atrial fibrillation in patients undergoing open-chest cardiac surgery
Route(s) of administration
Intramuscular use
Contact for public enquiries
Allergan Pharmaceutical International Limited

E-mail: EU_Reg_Affairs@allergan.com
Tel. +44 1628494444

Decision type
W: decision granting a waiver in all age groups for all conditions or indications


How useful was this page?

Add your rating